Compare USAS & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USAS | GLUE |
|---|---|---|
| Founded | 1998 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2004 | 2021 |
| Metric | USAS | GLUE |
|---|---|---|
| Price | $4.16 | $23.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $6.50 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 3.6M | 1.6M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $123,672,000.00 |
| Revenue This Year | $174.68 | N/A |
| Revenue Next Year | $53.17 | $2.45 |
| P/E Ratio | ★ N/A | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $0.87 | $4.12 |
| 52 Week High | $10.50 | $25.77 |
| Indicator | USAS | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 36.60 | 60.72 |
| Support Level | $3.53 | $17.66 |
| Resistance Level | $4.37 | $25.45 |
| Average True Range (ATR) | 0.29 | 1.68 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 15.66 | 68.98 |
Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).